← Feed

$XENE

3 theses
bullish 67%neutral 0%bearish 33%
Avg return (6m)
—
Win rate (6m)
— (0 resolved)
1d3d1w1m3m6m1y

Past performance does not predict future results. Informational only, not investment advice.

Recent theses

Prices as of Sep 18, 4:31 PM ET
$XENESEC Form 4bullish
Kelly Thomas Patrick · Chief Financial Officer at Xenon Pharmaceuticals Inc. · 3h agono track record yet
Long 15,000 shares of XENE
Bought 15,000 @ $37.32 avg · $559,740 · 2026-09-30

Form 4: Kelly Thomas Patrick bought XENE

Kelly Thomas Patrick (Chief Financial Officer at Xenon Pharmaceuticals Inc.) reported an open-market purchase of 15,000 shares of XENE at an average $37.32, roughly $559,740, in a Form 4 filed 2026-10-01.

Now $39.75as of Sep 18, 4:31 PM ET
View filing on SEC.gov →
$XENESEC Form 4bullish
MORTIMER IAN · PRESIDENT & CEO at Xenon Pharmaceuticals Inc. · 3h agono track record yet
Long 30,000 shares of XENE
Bought 30,000 @ $37.38 avg · $1,121,400 · 2026-09-30

Form 4: MORTIMER IAN bought XENE

MORTIMER IAN (PRESIDENT & CEO at Xenon Pharmaceuticals Inc.) reported an open-market purchase of 30,000 shares of XENE at an average $37.38, roughly $1,121,400, in a Form 4 filed 2026-10-01.

Now $39.75as of Sep 18, 4:31 PM ET
View filing on SEC.gov →
$XENESEC Form 4bearish
GANNON STEVEN · Xenon Pharmaceuticals Inc. · 49d agono track record yet
Sold 10,000 @ $64.06 avg · $640,550 · 2026-08-11

Form 4: GANNON STEVEN sold XENE

GANNON STEVEN (Director at Xenon Pharmaceuticals Inc.) reported an open-market sale of 10,000 shares of XENE at an average $64.06, roughly $640,550, in a Form 4 filed 2026-08-13.

At post $64.23Now $39.75-38.1% since postedas of Sep 18, 4:31 PM ET
1d-2.9%
3d-2.9%
1w-7.0%
1m-8.7%
3m—
6m—
1y—
View filing on SEC.gov →

End of results.